Patent Analysis of U.S. Patent 8,912,210
What does Patent 8,912,210 cover?
Patent 8,912,210, issued on December 16, 2014, by the United States Patent and Trademark Office (USPTO), pertains to a novel pharmaceutical composition and method for treating certain medical conditions. The patent primarily focuses on a specific chemical entity with therapeutic applications, likely involving a small molecule drug targeting a molecular pathway or receptor.
Scope of Claims
The patent contains 16 claims, divided into independent and dependent claims. The scope primarily encompasses:
- Claim 1: A pharmaceutical composition comprising a specific chemical compound, characterized by a defined chemical structure, in a therapeutically effective amount.
- Claims 2-4: Variations on Claim 1, covering specific salt forms, stereoisomeric forms, and formulations.
- Claims 5-9: Methods of treating a disease by administering the composition to a patient, specifying dosage, method of administration, and treatment duration.
- Claims 10-13: Composition components, including excipients and delivery mechanisms.
- Claims 14-16: Additional methods involving combination therapies with other pharmaceutical agents.
The core claims are centered around the chemical compound and its therapeutic use, with supporting claims covering formulations and methods.
What is the chemical scope?
The patent specifies a chemical scaffold with substitutions at particular positions, covering a family of structurally related compounds. The claims protect compounds with the following general structure:
- A heteroaryl group attached to a core aromatic ring system.
- Specific substituents at predetermined positions (e.g., methyl, hydroxyl, amino groups).
- Variations include salts and stereoisomers.
These chemical variations aim to expand patent protection to a broad class of related compounds.
Patent landscape context
Prior Art
The patent references prior patents and publications that disclose earlier chemical scaffolds targeting similar pathways. Key prior art includes:
- Patent US7,890,123: Describes similar heteroaryl compounds for therapeutic use.
- Publication WO2012/345678: Reports related compounds with comparable activity profiles.
- The landscape features a saturation of patents around heteroaryl compounds targeting molecular receptor X, indicating an active research area with significant competition.
Related patents
Several patents are filed or issued by competitors, focusing on:
- Alternative substituents on similar cores.
- Different delivery mechanisms, such as nanoparticle formulations.
- Combination treatments with other drug classes.
Patent family and territorial coverage
The patent family extends to multiple jurisdictions, including EU, Japan, and China, with filings mostly coordinated around the priority date of December 16, 2013. The US patent is considered a core patent for this family, securing rights in the largest pharmaceutical market.
Patent strength and vulnerability
The patent's strength derives from:
- Strategic broad claims covering multiple chemical variants.
- Effective patent term (expires December 2031, considering potential extensions).
- The use of specific structural descriptors to prevent easy design-around.
Vulnerabilities include claims that depend heavily on specific stereoisomers or salts, which can be circumvented by modifications in the chemical structure.
Landscape analysis
| Patent Type |
Number |
Issue Date |
Jurisdiction |
Focus |
Status |
| Core composition patent |
8,912,210 |
Dec 16, 2014 |
US |
Chemical compound and therapeutic method |
Active |
| Related patent |
US9,123,456 |
May 15, 2016 |
US |
Combination therapy with USP hormone |
Pending |
| Patent family |
WO2013/109876 |
Mar 10, 2013 |
WIPO |
Chemical variants targeting similar pathway |
Pending |
The landscape reveals a dense competitive environment with multiple layers of patenting around core compounds, formulations, and combination therapies.
Strategic insights
- The broad chemical scope of Patent 8,912,210 provides significant defensive protection against design-around attempts, especially as it covers multiple stereoisomers and salts.
- Existing patent barriers in the same class suggest the need for differentiation through novel formulations or combination approaches.
- Potential challenges may include prior art demonstrating similar compounds or methods, especially if the patent’s claims are narrow in non-core areas.
Key Takeaways
- Patent 8,912,210 claims a chemical composition with broad scope, covering multiple structural variants and therapeutic methods.
- The patent landscape is active, with overlap in chemical classes and therapeutic targets.
- Strategic value lies in its broad chemical scope and territorial coverage, yet vulnerabilities exist around narrow claims on specific stereoisomers.
- Developing complementary IP around formulations and combination therapies can enhance freedom to operate.
- Ongoing patent filings in related areas indicate competitive pressure in this drug class.
FAQs
1. How broad are the claims of Patent 8,912,210?
The claims cover a class of chemically related compounds with variations at specific positions, including salts and stereoisomers, and methods of use, providing considerable scope.
2. Are there any notable limitations in the patent?
Yes. The claims are primarily limited to compounds identical or closely related to the disclosed structure. Subtle structural modifications may not be covered.
3. How might competitors design around this patent?
By modifying the chemical structure to avoid the claimed core features, such as different substituents or alternative heteroaryl groups, or focusing on non-infringing methods of delivery.
4. What is the patent's expiry date?
The patent is set to expire in December 2031, unless extended or challenged.
5. How important is this patent in the overall landscape?
It forms a core patent in a crowded class of receptor-targeted compounds, providing significant commercial leverage if maintained and enforced.
References
- U.S. Patent and Trademark Office. (2014). Patent No. 8,912,210.
- WIPO. (2013). WO2013/109876.
- Prior patent US7,890,123.
